Seagen (Seagen) Receivables Turnover : 1.07 (As of Sep. 2023)

View and export this data going back to 2001. Start your Free Trial

What is Seagen Receivables Turnover?

The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Seagen's Revenue for the three months ended in Sep. 2023 was $649 Mil. Seagen's average Accounts Receivable for the three months ended in Sep. 2023 was $609 Mil. Hence, Seagen's Receivables Turnover for the three months ended in Sep. 2023 was 1.07.

Seagen Receivables Turnover Historical Data

The historical data trend for Seagen's Receivables Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Seagen Receivables Turnover Chart

Seagen Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Receivables Turnover

Get a 7-Day Free Trial

5.67

4.80

7.76

4.41

4.40

Seagen Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Receivables Turnover	Get a 7-Day Free Trial															1.10	1.07	1.04	1.12	1.07

Competitive Comparison of Seagen's Receivables Turnover

For the Biotechnology subindustry, Seagen's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Seagen's Receivables Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Seagen's Receivables Turnover distribution charts can be found below:

* The bar in red indicates where Seagen's Receivables Turnover falls into.

Seagen Receivables Turnover Calculation

Receivables Turnover measures the number of times a company collects its average accounts receivable balance.

Seagen's Receivables Turnover for the fiscal year that ended in Dec. 2022 is calculated as

	Receivables Turnover (A: Dec. 2022 )
=	Revenue	/	Average Total Inventories
=	Revenue (A: Dec. 2022 )	/ (	(Accounts Receivable (A: Dec. 2021 )	+	Accounts Receivable (A: Dec. 2022 ))	/	count )
=	1962.412	/ (	(389.256	+	501.912)	/	2 )
=	1962.412	/	445.584
=	4.40

Seagen's Receivables Turnover for the quarter that ended in Sep. 2023 is calculated as

	Receivables Turnover (Q: Sep. 2023 )
=	Revenue	/	Average Total Inventories
=	Revenue (Q: Sep. 2023 )	/ (	(Accounts Receivable (Q: Jun. 2023 )	+	Accounts Receivable (Q: Sep. 2023 ))	/	count )
=	648.65	/ (	(586.048	+	631.555)	/	2 )
=	648.65	/	608.8015
=	1.07

Seagen (NAS:SGEN) Receivables Turnover Explanation

An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.

Seagen Receivables Turnover Related Terms

Thank you for viewing the detailed overview of Seagen's Receivables Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.

Seagen (Seagen) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Seagen Inc (NAS:SGEN) » Definitions » Receivables Turnover

Comparable Companies

Traded in Other Exchanges

N/A

Address

21823 - 30th Drive South East, Bothell, WA, USA, 98021

Website

https://www.seagen.com

Seagen (formerly known as Seattle Genetics) is a biotech firm that develops and commercializes therapies to treat cancers. Seagen's therapies are based on antibody-drug conjugate technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. The company's lead product, Adcetris, has received approval for six indications to treat Hodgkin lymphoma and T-cell lymphoma. Other approved products include Padcev for bladder cancer, Tukysa for breast cancer, and Tivdak for cervical cancer. The company has several other oncology programs in pivotal trials. Seagen also licenses its antibody-drug conjugate technology to several leading biotechnology and pharmaceutical companies.

Executives

David R Epstein	director, officer: Chief Executive Officer	INTERNATIONAL FLAVORS & FRAGRANCES INC., 521 W. 57TH STREET, NEW YORK NY 10019
Vaughn B Himes	officer: See Remarks	C/O SEATTLE GENETICS, INC., 21823 30TH DRIVE SE, BOTHELL WA 98021
Charles R Romp	officer: EVP, Commercial	21823 30TH DRIVE SE, BOTHELL WA 98021
Roger D Dansey	officer: See Remarks	21823 30TH DRIVE SE, BOTHELL WA 98021
Jean I Liu	officer: GC & EVP, Legal Affairs	21823 30TH DRIVE SE, BOTHELL WA 98021
Todd E Simpson	officer: Chief Financial Officer
Daniel G Welch	director	4611 UNIVERSITY DR, 4 UNIVERSITY PLACE, DURHAM NC 27707
David W Gryska	director	749 N MARY AVE, SUNNYVALE CA 94085
Sandra M Swain	director	21823 30TH DRIVE SE, BOTHELL WA 98021
Ted W Love	director	C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT, SUITE 101, SOUTH SAN FRANCISCO CA 94080
Clay B Siegall	director, officer: President and CEO	21823 30TH DR SE, BOTHELL WA 98021
Baker Bros. Advisors Lp	director, 10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Felix Baker	director, 10 percent owner	BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Julian Baker	director, 10 percent owner	BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Baker Brothers Life Sciences Lp	director, 10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014